NCT05135000 - Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

March 20, 2024

Study Completion Date

April 25, 2024

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

LTP001

LTP001, 6 mg, was administered orally once daily in the morning

DRUG

Placebo

Placebo to LTP001 was administered once daily in the morning

Trial Locations (15)

13353

Novartis Investigative Site, Berlin

28041

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

29425

Medical Univ of South Carolina, Charleston

69120

Novartis Investigative Site, Heidelberg

85206

Pulmonary Associates PA, Mesa

C1025ABI

Novartis Investigative Site, Caba

01307

Novartis Investigative Site, Dresden

1081 HV

Novartis Investigative Site, Amsterdam

31 202

Novartis Investigative Site, Krakow

91-347

Novartis Investigative Site, Lodz

50-556

Novartis Investigative Site, Wroclaw

08036

Novartis Investigative Site, Barcelona

S10 2JF

Novartis Investigative Site, Sheffield

SW3 6PH

Novartis Investigative Site, London